Attenuation of age- and sucrose-induced insulin resistance and syndrome X by a synergistic antioxidant cocktail: the AMIS syndrome and HISS hypothesis.
Absence of meal-induced insulin sensitization (AMIS) results in a predictable progression of dysfunctions, including postprandial hyperglycemia, compensatory hyperinsulinemia, resultant hyperlipidemia, increased oxidative stress, and obesity, progressing to syndrome X and diabetes. To one year of age, rats show a slow development of AMIS, but this can be potentiated by addition of a low-dose sucrose supplement to the diet. Provision of a synergistic antioxidant cocktail consisting of S-adenosylmethionine, vitamin E, and vitamin C (Samec) attenuates the rate and extent of development of AMIS in both normal aging animals and in aging animals on the sucrose diet. Adiposity, assessed from weighed regional fat masses and from bioelectrical impedance to estimate whole-body adiposity, correlated strongly with AMIS (r2 = 0.7-0.8). Rats given the sucrose supplement had accelerated AMIS and developed fasting hyperinsulinemia and postprandial hyperglycemia, hyperlipidemia, hyperinsulinemia, and adiposity. Samec completely compensated for the negative impact of this sucrose supplement and attenuated development of the associated dysfunctions. AMIS is explained by the HISS (hepatic insulin-sensitizing substance) hypothesis, which is outlined in the paper.
Lautt
W Wayne
WW
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Manitoba, 753 McDermot Avenue, Winnipeg, MB R3E 0T6, Canada. wlautt@cc.umanitoba.ca
Ming
Zhi
Z
Legare
Dallas J
DJ
D000375:Aging / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage*; D001685:Biological Factors / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D004357:Drug Synergism; D004435:Eating / Q000502:physiology*; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D024821:Metabolic Syndrome / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D011237:Predictive Value of Tests; D051381:Rats; D013395:Sucrose / Q000008:administration & dosage*
D000975:Antioxidants; D001685:Biological Factors; D013395:Sucrose
Int J Clin Pract Suppl. 2003 Mar;(134):18-27
12793594
J Gerontol. 1956 Jul;11(3):298-300
13332224
Obes Res. 2004 Aug;12(8):1352-9
15340119
Invest Ophthalmol Vis Sci. 2007 Feb;48(2):479-85
17251439
Blood Coagul Fibrinolysis. 2007 Jun;18(4):353-9
17473577
Am J Physiol. 1996 Aug;271(2 Pt 1):E246-52
8770017
Can J Physiol Pharmacol. 1998 Dec;76(12):1080-6
10326829
J Comp Neurol. 2001 Jun 4;434(3):358-77
11331534
Nature. 2006 Apr 13;440(7086):944-8
16612386
Am J Physiol. 1996 May;270(5 Pt 1):E858-63
8967475
J Biochem. 1974 Jan;75(1):93-103
4151174
Aust N Z J Med. 1990 Aug;20(4):570-7
2222350
Diabetologia. 2005 May;48(5):976-83
15830187
Proc West Pharmacol Soc. 1998;41:37-8
9836234
Am J Physiol Gastrointest Liver Physiol. 2001 Jul;281(1):G29-36
11408252
Br J Nutr. 2000 Mar;83 Suppl 1:S71-7
10889795
Exp Physiol. 2007 Nov;92(6):1005-13
17644704
Diabetes Metab Res Rev. 2001 Jan-Feb;17(1):19-26
11241888
Exp Gerontol. 2008 Aug;43(8):790-800
18538970
J Gerontol A Biol Sci Med Sci. 2008 Jun;63(6):560-5
18559629
Naunyn Schmiedebergs Arch Pharmacol. 2005 Jul;372(1):71-8
16059734
Br J Pharmacol. 2006 Apr;147(8):959-65
16491098
Physiol Rev. 1979 Jul;59(3):527-605
37532
Can J Physiol Pharmacol. 2008 Dec;86(12):880-8
19088809
Can J Physiol Pharmacol. 2009 Oct;87(10):873-82
20052013
Br J Nutr. 2006 Feb;95(2):288-95
16469144
Obesity (Silver Spring). 2007 Jul;15(7):1685-93
17636086
Nature. 2001 Dec 13;414(6865):813-20
11742414
Free Radic Biol Med. 2000 Aug;29(3-4):222-30
11035250
J Cardiovasc Pharmacol. 1992;20 Suppl 8:S26-8
1283766
Ther Clin Risk Manag. 2007 Oct;3(5):761-70
18473001
Obes Res. 2005 Apr;13(4):717-28
15897481
Am J Physiol Gastrointest Liver Physiol. 2003 Apr;284(4):G588-94
12466146
J Gerontol. 1983 Nov;38(6):673-7
6630900
Gen Pharmacol. 1980;11(4):343-5
6995222
Diabetes. 1990 Nov;39(11):1420-4
2227114
Exp Eye Res. 2005 Oct;81(4):478-91
15935343
Am J Physiol. 1999 Jul;277(1):G101-8
10409156
Obes Res. 2001 Aug;9(8):423-31
11500522
Biochem J. 2004 Aug 15;382(Pt 1):131-6
15142037
Diabetes. 1997 Oct;46(10):1579-85
9313753
FASEB J. 2006 Apr;20(6):631-7
16581971
Biochem J. 1988 Nov 15;256(1):205-12
2851978
Essays Biochem. 2006;42:75-88
17144881
Endocrinol Metab Clin North Am. 1995 Jun;24(2):255-72
7656891
Am J Physiol Endocrinol Metab. 2002 Feb;282(2):E286-96
11788359
FASEB J. 1999 Jun;13(9):1055-64
10336888
Can J Physiol Pharmacol. 2002 Jan;80(1):8-12
11911229
Auton Neurosci. 2007 Oct 30;136(1-2):1-19
17537681
Can J Physiol Pharmacol. 1999 Aug;77(8):553-62
10543718
Obesity (Silver Spring). 2007 Feb;15(2):314-21
17299103
Can J Appl Physiol. 2004 Dec;29(6):808-29
15630152
Am J Cardiol. 2007 Aug 1;100(3):524-7
17659940
Free Radic Biol Med. 2006 Feb 15;40(4):617-24
16458192
Metabolism. 2002 May;51(5):544-8
11979383
Br Heart J. 1986 Apr;55(4):348-54
3964501
J Auton Pharmacol. 1995 Oct;15(5):361-9
8744976
Circulation. 2005 Oct 25;112(17):2735-52
16157765
Med Res Rev. 2003 Jan;23(1):1-14
12424750
Prog Clin Biol Res. 1989;304:259-75
2675032
J Pharmacol Sci. 2004 May;95(1):9-17
15153645
J Cardiometab Syndr. 2006 Fall;1(5):362-3
17679794
Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3474-8
16877418